Borges Jairo Lins
Seção clínica de Cardiogeriatria, Instituto Dante Pazzanese de Cardiologia de São Paulo.
Arq Bras Cardiol. 2005 Oct;85 Suppl 5:36-41. Epub 2006 Jan 2.
Combination of statins with niacin appears to be an attractive association, in the presence of mixed dyslipidemia with low HDL-c levels, when monotherapy is insufficient to achieve target lipid levels. Clinical benefits were observed by the combination of statins with niacin in the FATS, HATS and ARBITER 2 trials, showing attenuation of atherosclerosis development and/or reduction in coronary events following favorable lipid changes. In general, this combination can be well-tolerated. Recommendations for appropriate monitoring of liver and muscle enzymes are important to reduce the rate of side effects. In addition, careful titration of each drug is recommended.
在混合性血脂异常且高密度脂蛋白胆固醇（HDL - c）水平较低、单一疗法不足以达到目标血脂水平的情况下，他汀类药物与烟酸联合使用似乎是一种有吸引力的联合方式。在FATS、HATS和ARBITER 2试验中，他汀类药物与烟酸联合使用观察到了临床益处，显示出在血脂改善后动脉粥样硬化发展的减缓及/或冠状动脉事件的减少。总体而言，这种联合用药耐受性良好。建议对肝酶和肌酶进行适当监测，这对于降低副作用发生率很重要。此外，建议对每种药物进行仔细滴定。
